Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 9;11(1):2034257. doi: 10.1080/2162402X.2022.2034257

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 5. — The accumulation of intratumoral PD-1+ DCs was correlated with a favorable response to PD-1 blockade.

(a) The percentages of IL-12+, IL-1β+ and TNF-α+ cells in PD-1+ or PD-1- DCs from CC tumors before and after treatment with pembrolizumab. (b) Representative flow cytometric histograms showing IL-12, IL-1β and TNF-α expression on PD-1+ or PD-1- DCs in CC before and after treatment with pembrolizumab. (c) The apoptosis rate of tumor cells from high and low PD-1+ DC expressers after treatment, as determined by Annexin V-PI staining. The fold change was calculated as the ratio between the pembrolizumab group and the control group. (d,e) The percentages of Ki67+, CD107a+, GZMB+, perforin+, TNF-α+, IFN-γ+ and IL-2+ cells in CD4 + T cells (D) or CD8 + T cells (E) from high and low PD-1+ DC expressers. The fold change was calculated as the ratio between the pembrolizumab group and the control group.